Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic debilitating condition with no cure that shares commonality with long-COVID. This review examines current understanding of long-COVID symptoms, characteristics of the affected population, the connection with ME/CFS, and the potential for salubrinal, an agent known for its influence on cellular stress pathways, to mitigate these disorders It also describes the historical development and mechanism of action of salubrinal, to mitigate endoplasmic reticulum (ER)/cellular stress responses, that could potentially contribute to symptom improvement in both ME/CFS and long-COVID patients. Further research and clinical trials are warranted to advance our understanding of the potential role of salubrinal in improving the quality of life for individuals with long-COVID-related ME/CFS symptoms as well as ME/CFS patients.
| Original language | English |
|---|---|
| Pages (from-to) | 466-478 |
| Number of pages | 13 |
| Journal | Trends in Molecular Medicine |
| Volume | 31 |
| Issue number | 5 |
| DOIs | |
| State | Accepted/In press - Oct 2024 |
Bibliographical note
Publisher Copyright:© 2024 Elsevier Ltd
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
ASJC Scopus Subject Areas
- Molecular Medicine
- Molecular Biology
Keywords
- endoplasmic reticulum/cellular stress pathways
- eukaryotic initiation factor 2α (eIF2α)
- long-COVID
- mitochondrial dysfunction
- myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- salubrinal
Disciplines
- Molecular Biology
- Medical Molecular Biology